Details of the Drug

General Information of Drug (ID: DMARHU4)

Drug Name
UCART-22
Indication
Disease Entry ICD 11 Status REF
B-cell acute lymphoblastic leukaemia 2B33.3 Phase 1 [1]
Drug Type
CAR T Cell Therapy
Cross-matching ID
TTD ID
D7C3JA

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-cell receptor CD22 (CD22) TTM6QSK CD22_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease B-cell acute lymphoblastic leukaemia
ICD Disease Classification 2B33.3
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-cell receptor CD22 (CD22) DTT CD22 1.89E-11 -0.21 -0.58
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04150497) Phase I Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Cellectis.